FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression.

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Klintmalm, GB; Kaplan, B; Kirk, AD

Published Date

  • April 2019

Published In

Volume / Issue

  • 19 / 4

Start / End Page

  • 971 - 972

PubMed ID

  • 30552744

Pubmed Central ID

  • 30552744

Electronic International Standard Serial Number (EISSN)

  • 1600-6143

Digital Object Identifier (DOI)

  • 10.1111/ajt.15215

Language

  • eng

Conference Location

  • United States